Back to today’s briefing

Story perspectives

FDA Targets Chest-Binder Sellers in Trans Rights Controversy

12/20/2025

26 6 Full Breakdown

Summary

Story summary

The U.S. Food and Drug Administration issued warning letters to 11 chest-binder sellers, labeling them misbranded medical devices, and giving them 15 days to respond.
This action is part of a broader crackdown on youth gender-affirming care.
The FDA says these products are intended for medical use.
No chest binder is marketed exclusively for minors.
Critics, including the Human Rights Campaign, say the actions threaten trans rights.

1 of 1

Story summary

The U.S. Food and Drug Administration issued warning letters to 11 chest-binder sellers, labeling them misbranded medical devices, and giving them 15 days to respond.
This action is part of a broader crackdown on youth gender-affirming care.
The FDA says these products are intended for medical use.
No chest binder is marketed exclusively for minors.
Critics, including the Human Rights Campaign, say the actions threaten trans rights.